WYWenlei Yang

Wenlei Yang

*This is an algorithmically generated author record based on publicly available information.

Wenlei Yang has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Zhonghu He

    State Key Laboratory of Molecular Oncology, Department of Genetics, Peking University Cancer Hospital & Institute, Beijing, China

    4 shared publications
  • Linlin Wang

    Peking University

    3 shared publications
  • Mengfei Liu

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genetics, Peking University Cancer Hospital and Institute, Beijing, China

    3 shared publications
  • Yang Ke

    State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Genetics, Peking University Cancer Hospital and Institute, Beijing, China

    3 shared publications
  • Aiguo Ren

    Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

    2 shared publications
  • Chao Shi

    People's Hospital of Ningxia Hui Autonomous Region Ningxia Medical University Yinchuan Ningxia Hui Autonomous Region China

    2 shared publications

Latest Publications

  • Open Access

    Participation Barriers in Risk-Stratified Endoscopic Screening for Upper GI Cancer: A Mixed-Methods Study

    by Zeyu Yan, Lei Chen, Jinbao Ma, Mengfei Liu, Zhen Liu, Mei Li, Man Tat Alexander Ng, Yi Yang, Yine Zhang, Yingying Liang, et al.

    PURPOSE: The purpose of this study was to identify participation determinants among high-risk individuals in risk-stratified upper GI (UGI) cancer screening. METHODS: This sequential mixed-methods study was conducted in a population-based UGI cancer screening program in Ningxia Province, China. It integrates quantitative and qualitative methods to comprehensively examine participation determinants. Between April and December 2023, quantitative data were collected from 2,571 high-risk individuals identified by validated diagnostic models. Subsequently, 42 high-risk individuals (median age: 63.0 years; 81.0% male) were interviewed by stratified purposive sampling from March to April 2024. Logistic regression explored factors associated with screening adherence. Thematic analysis of qualitative interviews integrated quantitative findings using the Capability, Opportunity, and Motivation-Behavior framework. RESULTS: Of the high-risk individuals, 52.8% declined endoscopy. Nonparticipation was significantly associated with older age (adjusted odds ratio [aOR], 1.28 [1.06-1.54]), male sex (1.31 [1.01-1.70]), Hui ethnicity (1.35 [1.12-1.62]), nonsmoking (1.23 [1.01-1.50]), nondrinking (1.36 [1.09-1.71]), no family history of UGI cancer (1.48 [1.20-1.84]), fewer UGI symptoms (2.64 [2.19-3.18]), and no prior UGI examination (1.67 [1.37-2.05]). In the qualitative phase, seven key barriers were identified, including insufficient knowledge about UGI cancer and risk assessment, physical limitations, low perceived risk, gastroscopy-related fears, cost concerns, time constraints, and inadequate information. CONCLUSION: Addressing limited knowledge and program accessibility may improve participation and real-world implementation of risk-stratified UGI cancer screening.

  • Reply to C. Xia et al

    by Wenlei Yang, Mengfei Liu, Zhonghu He, Yang Ke


  • Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial

    by Mengfei Liu, Wenlei Yang, Chuanhai Guo, Zhen Liu, Fenglei Li, Anxiang Liu, Haijun Yang, Lin Shen, Qi Wu, Liping Duan, et al.

    PURPOSE: To evaluate the effectiveness of endoscopic screening against incidence of and mortality from esophageal squamous cell carcinoma (ESCC). METHODS: From January 2012 to September 2016, we conducted a community-based cluster randomized controlled trial involving permanent residents age 45-69 years in a high-risk region for ESCC in northern China. A total of 668 targeted villages were randomly assigned in a 1:1 ratio to the screening group (offered Lugol's chromoendoscopy) or control group (no screening). Intention-to-treat and per-protocol analyses were performed to compare esophageal cancer (EC) incidence and mortality between the two groups. The per-protocol analysis adjusted for nonadherence to the screening procedure. RESULTS: A total of 33,847 participants were included in the analysis: 17,104 in the screening group, 15,165 (88.7%) of whom underwent screening, and 16,743 in the control group. During a maximum follow-up of 9 years, EC incidence in the screening and control groups were 60.9 and 72.5 per 100,000 person-years, respectively; mortality in the screening and control groups were 29.7 and 32.4 per 100,000 person-years, respectively. Compared with the control group, the incidence and mortality of the screening group reduced by 19% (adjusted hazard ratio [aHR], 0.81 [95% CI, 0.60 to 1.09]) and 18% (aHR, 0.82 [95% CI, 0.53 to 1.26]), respectively, in the intention-to-treat analysis; and by 22% (aHR, 0.78 [95% CI, 0.56 to 1.10]) and 21% (aHR, 0.79 [95% CI, 0.49 to 1.30]), respectively, in the per-protocol analysis. CONCLUSION: With a 9-year follow-up, our trial suggests that chromoendoscopic screening induces modest reductions in EC incidence and mortality. A more efficient strategy for EC screening and subsequent patient management should be established to guarantee the effectiveness of endoscopic screening.


  • Open Access

    PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study

    by Mifen Chen, Zhenghang Wang, Zimin Liu, Ting Deng, Xiaodong Wang, Zhiwei Chang, Qi Zhang, Wenlei Yang, Ning Liu, Zhi Ji, et al.

    PURPOSE: To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers. METHODS: We retrospectively recruited patients with MSI/dMMR gastrointestinal cancer who received anti–PD-1/PD-L1 with or without chemotherapy and compared objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) of PD-1/PD-L1 inhibitor plus chemotherapy (chemo-anti–PD-1/PD-L1 group) and PD-1/PD-L1 inhibitor alone (anti–PD-1/PD-L1 group). Propensity score–based overlap weighting analysis was conducted to adjust the baseline covariable imbalance. Sensitivity analysis was performed to confirm the stability of the results by propensity score matching and multivariable Cox and logistic regression models. RESULTS: A total of 256 patients were eligible, with 68 and 188 receiving chemo-anti–PD-1/PD-L1 and anti–PD-1/PD-L1, respectively. The chemo-anti–PD-1/PD-L1 group showed significant improvements versus the anti–PD-1/PD-L1 group in ORR (61.8% v 38.8%; P = .001), DCR (92.6% v 74.5%; P = .002), PFS (median PFS [mPFS], not reached [NR] v 27.9 months; P = .004), and OS (median OS [mOS], NR v NR; P = .014). After overlap weighting, the improvements tended to be more significant with chemo-anti–PD-1/PD-L1 versus anti–PD-1/PD-L1 in ORR (62.5% v. 38.3%; P < .001), DCR (93.8% v 74.2%; P < .001), PFS (mPFS, NR v 26.0 months; P = .004), and OS (mOS, NR v NR; P = .010). These results were solidified through sensitivity analysis. CONCLUSION: Chemo-anti–PD-1/PD-L1 is superior to anti–PD-1/PD-L1 in MSI/dMMR gastrointestinal cancers with improved efficacy.


  • Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer From a Real-world Multicenter Study

    by Fangfang Liu, Wenlei Yang, Wei Yang, Ruiping Xu, Lei Chen, Yu He, Zhen Liu, Fuyou Zhou, Bolin Hou, Liqun Zhang, et al.

    Objective: To evaluate the long-term and short-term outcomes of MIE compared with OE in localized ESCC patients in real-world settings. Background: MIE is an alternative to OE, despite the limited evidence regarding its effect on long-term survival. Methods: We recruited 5822 consecutive patients with resectable ESCC in 2 typical high-volume centers in southern and northern China, 1453 of whom underwent MIE. Propensity score-based overlap weighted regression adjusted for multifaceted confounding factors was used to compare outcomes in the MIE and OE groups. Results: Five-year OS was 62.7% in the MIE group and 57.7% in the OE group. The overlap weighted Cox regression showed slightly better OS in the MIE group (hazard ratio 0.93, 95% confidence interval: 0.82–1.06). Although duration of surgery was longer and treatment cost higher in the MIE group than in the OE group, the number of lymph nodes harvested was larger, the proportion of intraoperative blood transfusions lower, and postoperative complications less in the MIE group. 30-day (risk ratio [RR] 0.77, 0.381.55) and 90-day (RR 0.79, 0.46–1.35) mortality were lower in the MIE group versus the OE group, although not statistically significant. These findings were consistent across different analytic approaches and subgroups, notably in the subset of ESCC patients with large tumors. Conclusions: MIE can be performed safely with OS comparable to OE for patients with localized ESCC, indicating MIE may be recommended as the primary surgical approach for resectable ESCC in health facilities with requisite technical capacity.


  • Open Access

    Hypermethylation of WNT3A gene and non-syndromic cleft lip and/or palate in association with in utero exposure to lead: A mediation analysis

    by Wenlei Yang, Yingnan Guo, Wenli Ni, Tian Tian, Lei Jin, Jufen Liu, Zhiwen Li, Aiguo Ren, Linlin Wang


  • Maternal hypertensive disorders in pregnancy and risk of hypoxic-ischemia encephalopathy

    by Wenlei Yang, Linlin Wang, Tian Tian, Lijun Liu, Lei Jin, Jianmeng Liu, Aiguo Ren

    Hypoxic–ischemic encephalopathy (HIE) is one of the most serious birth complications for neonates. Few studies reported the relationship between maternal blood pressure disorders and risk of neonat...


  • Genetic variants in GRHL3 and risk for neural tube defects: A case–control and case–parent triad/control study

    by Wenlei Yang, Yanhui Xiao, Tian Tian, Lei Jin, Linlin Wang, Aiguo Ren

    Background: Neural tube defects (NTDs) are the most common severe birth defects with complex etiologies. Previous studies conducted on animals have suggested that the Grhl3 gene is essential for closure of the spinal neural tube, but little evidence from human studies on the variants of GRHL3 gene has been provided, especially the common genetic variants.Methods: To investigate the relationship between common genetic variants of GRHL3 and the risk for NTDs, we performed a case–control study and a case–parent triad/control study. Fast‐target enrichment sequencing was performed to screen exon regions from 503 NTD cases, and three tag SNPs (single nucleotide polymorphisms, including rs12030057, rs2486668, and rs545809) were selected according to the sequencing results. Then, Sequenom MassARRAY genotyping was performed in 757 case parents and 519 controls to obtain genotype information of the target variant sites among all NTD triads and controls.Results: The genotype distributions of all SNPs were in accordance with Hardy–Weinberg Equilibrium (HWE) in the control population. In the case–control study, significant associations were found between C27G genetic variants on rs2486668 and risk for spina bifida and encephalocele, respectively, under different genetic models. Consistently, in the case–parent triad/control study, GG genotype on rs2486668 was associated with increased risk for spina bifida, with a RR of 2.15 (95% CI: 1.20–3.83). However, no parent‐of‐origin effect was found for any tag SNPs.Conclusion: The GRHL3 C67G missense variant may increase the risk for spina bifida and encephalocele phenotypes.